Association of antiretroviral therapy with fibrinogen levels in HIV-infection

Background:HIV infection is associated with an increased risk of coronary artery disease, but the contribution of inflammation versus antiretroviral drugs is not well understood. Fibrinogen is an inflammatory factor associated with atherosclerosis. Methods:A total of 1131 HIV-infected patients and 281 controls [from the Coronary Artery Risk Development in Young Adults (CARDIA) study, a population-based study of cardiovascular risk assessment] in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) had plasma fibrinogen levels measured. Multivariable linear regression identified factors associated with fibrinogen. Results:HIV-infected patients had higher levels of fibrinogen compared with controls (males: 25 mg/dl higher, P = 0.006; females: 21 mg/dl higher, P = 0.39). Among HIV-infected persons, median levels of fibrinogen were 11% higher in patients currently using any protease inhibitor (PI) compared with those not using a PI (P < 0.0001). The strongest univariate associations were with the individual PIs, ritonavir and indinavir. Patients taking indinavir boosted with ritonavir had median fibrinogen levels 8% higher than those on indinavir alone (P = 0.049). Lower levels of fibrinogen were seen in those HIV-infected patients currently using any nonnucleoside reverse transcriptase inhibitor (NNRTI) compared to those not using an NNRTI (nevirapine −14.4%, P < 0.0001; efavirenz −7%, P = 0.0002). The associations of ritonavir, indinavir, efavirenz and nevirapine with fibrinogen levels persisted after multivariable analysis and were independent of other antiretroviral use. Conclusion:Protease inhibitor use is associated with elevated fibrinogen levels which may contribute to increased risk of atherosclerosis in HIV-infected patients. Conversely, NNRTI use is associated with lower fibrinogen levels which may decrease risk of atherosclerosis.

[1]  Anne L. Taylor,et al.  Coronary heart disease in HIV-infected individuals. , 2003, Journal of acquired immune deficiency syndromes.

[2]  O. Kirk,et al.  Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[3]  Steven B Heymsfield,et al.  Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. , 1998, American journal of physiology. Endocrinology and metabolism.

[4]  S. Weisnagel,et al.  Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. , 2005, The American journal of cardiology.

[5]  Metabolic,et al.  Fat Distribution in Women With HIV Infection , 2006, Journal of acquired immune deficiency syndromes.

[6]  Benjamin J Cowling,et al.  Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use , 2006, AIDS.

[7]  R. Parker,et al.  The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults , 2004, AIDS.

[8]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.

[9]  S. Heymsfield,et al.  Fat Distribution in Men With HIV Infection , 2005, Journal of acquired immune deficiency syndromes.

[10]  D. Bastelica,et al.  Adipose Tissue and Atherothrombosis , 2003, Pathophysiology of Haemostasis and Thrombosis.

[11]  M. Schambelan,et al.  Metabolic effects of indinavir in healthy HIV-seronegative men , 2001, AIDS.

[12]  R. Parker,et al.  Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically , 2006, AIDS.

[13]  S. Sidney,et al.  The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. , 2006, American journal of epidemiology.

[14]  H. Schmidt,et al.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. , 1999, AIDS.

[15]  R. Tracy,et al.  Inflammation markers and coronary heart disease. , 1999, Current opinion in lipidology.

[16]  M. Schambelan,et al.  The metabolic effects of lopinavir/ritonavir in HIV-negative men , 2004, AIDS.

[17]  M. Schambelan,et al.  Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Sidney,et al.  Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV‐1 Infection? , 2002, Journal of acquired immune deficiency syndromes.

[19]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[20]  M. Schambelan,et al.  Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers , 2007, AIDS.

[21]  W. Kannel.  Overview of hemostatic factors involved in atherosclerotic cardiovascular disease , 2005, Lipids.

[22]  M. Bo,et al.  Body fat is the main predictor of fibrinogen levels in healthy non-obese men. , 2004, Metabolism: clinical and experimental.

[23]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[24]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[25]  E. Sandström,et al.  Hypofibrinolytic State in HIV‐1‐Infected Patients Treated With Protease Inhibitor‐Containing Highly Active Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.